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Background: We compared aortic stiffness, aortic impedance and pressure from wave reflections in the setting of
bicuspid aortic valve (BAV) to the tricuspid aortic valve (TAV) in the absence of proximal aortic dilation. We
hypothesized BAV is associated with abnormal arterial stiffness.
Methods: Ten BAV subjects (47 ± 4 years, 6 male) and 13 TAV subjects (46 ± 4 years, 10 male) without significant
aortic valve disease were prospectively recruited. Characteristic impedance (Zc) was derived from echocardiographic
images and pulse wave Doppler of the left ventricular outflow tract. Applanation tonometry was performed to
obtain pulse wave velocity (PWV) at several sites as measures of arterial stiffness and augmentation index (AIx) as a
measure of wave reflection.
Results: There were no significant differences between BAV and TAV subjects with regard to heart rate or blood
pressure. Zc was similar between BAV and TAV subjects (p=0.25) as was carotid-femoral pulse wave velocity (cf-
PWV) and carotid-radial PWV (cr-PWV) between BAV and TAV subjects (p=0.99). Carotid AIx was significantly higher
in BAV patients compared with TAV patients (14.3 ± 4.18% versus -3.02 ± 3.96%, p=0.007).
Conclusions: Aortic stiffness and impedance is similar between subjects with BAV and TAV with normal aortic
dimensions. The significantly higher carotid AIx in BAV, a proxy of increased pressure from wave reflections, may
reflect abnormal vascular function distal to the aorta.
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Bicuspid aortic valve (BAV) is one of the most common
congenital cardiac abnormalities, occurring in 1-2% of
the population [1]. A high heritability index [2] and as-
sociation with variants in several genes that regulate
heart development [3,4] suggest that BAV is regulated
by genetic factors. BAV is also associated with abnormal-
ities of the thoracic aorta including dilation, aneurysm
formation, coarctation, and dissection [5,6]. More than
half of young patients with normally functioning BAV
have echocardiographic evidence of aortic dilatation [7],* Correspondence: ghuggins@tuftsmedicalcenter.org
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reproduction in any medium, provided the orand progressive aortic dilation may develop in children
[8]. The degree of aortic dilation appears out of propor-
tion to valve dysfunction [9,10], and aortic valve replace-
ment does not halt the risk of subsequent aortic
complications [7,11]. Finally, aortic aneurysm can
present in BAV families as an autosomal dominant trait
with incomplete penetrance [12], and data suggests that
genetic mutations may contribute to aortic aneurysm in
the setting of a BAV [13]. Family studies, however, have
not supported shared underlying genetic effects contrib-
uting to both BAV and aortic dilation [14]. Thus, evi-
dence would support there being intrinsic abnormalities
of aortic stiffness, perhaps caused by genetic factors that
may invariably contribute to the risk of dilation and po-
tential for aneurysm formation in BAV.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measuring aortic stiffness in a cohort of BAV and TAV
patients with normal proximal ascending aorta dimen-
sion. In order to further investigate vascular function in
BAV, we also measured augmentation index (AIx) as a
proxy of pressure from wave reflections and carotid-
brachial/ carotid-radial pulse-wave velocity (cb-PWV) as
indications of peripheral arterial stiffness.
Methods
Subject selection
Study subjects were prospectively recruited from the
outpatient echocardiography laboratory at Tufts Medical
Center. Valve morphology was assessed using two-
dimensional echocardiography in standard long and
short axis views. Exclusion criteria were: (i) Marfan syn-
drome or history of familial aortic aneurysm, (ii) internal
ascending aortic diameter greater than 4.5 cm based on
echocardiographic measurements, (iii) left ventricular
ejection fraction <55%, (iv) moderate or severe aortic
stenosis, (v) moderate or severe aortic regurgitation, (vi)
aortic valve replacement, (vii) aortic coarctation, and
(viii) blood pressure >160/90 mmHg. Ten consecutive
BAV subjects (6 males) and 13 TAV controls (10 males)
that provided consent were enrolled in the study.
Ethical clearance and consent
This study was ethically approved by the Tufts Medical
Center/Tufts University Institutional Review Board after
meeting the required ethical standards in compliance
with the Helsinki Declaration. Every prospective partici-
pant was explained the purpose of the research and was
requested to participate freely. A consent form containing
details of the study regarding main purpose, role of partic-
ipants, and benefits associated with participating in the
study (if any) was given to each prospective participant.
Those who agreed to participate in the study signed a
written consent form. Patients who did not agree to par-
ticipate in the study were not denied any services or
treated with partiality.
Echocardiography and tonometry measurements
Subjects were studied in the supine position using a tonom-
etry machine (Cardiovascular Engineering, Inc., Norwood,
MA) and an echocardiogram machine (Philips IE33 echo-
cardiography machine). Arterial tonometry with ECG was
use to record pressure waveforms from the brachial, radial,
femoral, and carotid arteries using a custom transducer as
previously described [15,16]. Two-dimensional echocardio-
graphic images of the left ventricular outflow tract (LVOT)
obtained from the parasternal long axis view were studied
to measure the LVOT diameter. Pulsed Doppler of the
LVOT from an apical 5-chamber view was recorded to
measure LVOT blood velocity.Calculation of Pulse Wave Velocity (PWV)
Signal averaged pressure waveforms (NiHem Noninva-
sive Hemodynamics Workstation v4.50, Cardiovascular
Engineering) were superimposed on one another. The
body surface distances between the suprasternal notch
and pulse recording sites were measured using a meas-
uring tape and calipers. PWV was calculated as the ratio
of the distance (Δd) between the carotid artery and a
distal arterial site to the relative time interval (Δt) be-
tween the foot of the carotid pulse wave and the distal
arterial pulse wave (PWV = Δd/ Δt, cm/sec) [15,16]. We
directly measured and recorded carotid-femoral PWV
(cf-PWV), carotid-brachial PWV (cb-PWV) and carotid-
radial PWV (cr-PWV).
Calculation of augmentation index
The carotid pressure waveform obtained from applanation
tonometry was assessed to determine peak pressure
(ΔPtotal) and the inflection point created by pressure aug-
mentation of the peripherally reflected wave (ΔPAI). The
augmentation index (AIx) was computed as the ratio of
augmentation pressure to peak pressure expressed as a
percentage (AIx =ΔPAI/ ΔPtotal). If the inflection point oc-
curs before peak pressure, AIx is expressed as positive per-
centage; if the inflection point occurs after peak pressure,
AIx is expressed as a negative percentage [15]. Time to in-
flection is presented as a measure of wave travel timing.
Calculation of Characteristic Impedance: LVOT absolute
flow (ΔV) was calculated as the product of cross sec-
tional area, calculated from the LVOT diameter, and the
LVOT blood flow velocity. The pressure differential (ΔP)
created during the same time interval was estimated
from ECG gated signal averaged pressure waveform ac-
quired from applanation tonometry of the carotid artery.
Characteristic impedance (Zc) was then calculated as the
ratio of pressure to flow (Zc=ΔP/ΔV) [15,16].Calculation of arterial elastance and peak wall shear
Peak wall shear rate was calculated as 4 × (peak aortic
velocity/ aortic root diameter). Cardiac dimensions were
assessed using standard 2-dimensional echocardio-
graphic techniques (Simpson’s method). Effective arterial
elastance (Ea) was estimated as end systolic pressure /
stroke volume and used as a measure of arterial pulsatile
load related to vascular input impedance [17]. End sys-
tolic pressure was obtained from the carotid pressure
waveform. Stroke volume was calculated as end-diastolic
volume – end systolic volume from 2D echo.
Statistical analyses
A priori significance was set at p < 0.05. Normality of
distribution was confirmed using Kolmogorov-Smirnov
and Shapiro-Wilk tests. Group comparisons were made
Table 1 Demographics
Descriptives BAV TAV p-value
Age 46.5 ± 11.6 46.3 ± 15.1 0.97
Males (n, %) 6 (60%) 10 (77%) 0.40
Height (in) 66.0 ± 4.2 70.0 ± 3.5 0.02*
Weight (lbs) 188.9 ± 52.9 180.3 ± 48.9 0.69
Body mass index 30.1 ± 6.8 25.8 ± 5.8 0.10
Body surface area (m3) 1.98 ± 0.32 1.99 ± 0.32 0.93
Systolic blood pressure (mmHg) 118.3 ± 14.4 120.7 ± 13.4 0.69
Diastolic blood pressure (mmHg) 71.7 ± 11.6 70.2 ± 7.9 0.72
Pulse pressure (mmHg) 46.6 ± 11.4 50.6 ± 13.0 0.46
Mean arterial pressure (mmHg) 87.2 ± 11.4 87.0 ± 7.9 0.97
Heart rate (bpm) 64.1 ± 6.4 62.4 ± 12.6 0.70
Ejection fraction (%) 59.0 ± 3.1 58.5 ± 3.2 0.67
Aortic root diameter (cm) 3.14 ± 0.52 3.06 ± 0.34 0.75
Aortic root index (cm/m3) 1.59 ± 0.18 1.56 ± 0.26 0.69
Ascending aortic diameter (cm) 3.24 ± 0.46 2.87 ± 0.46 0.07
Ascending aortic index (cm/m3) 1.67 ± 0.35 1.45 ± 0.20 0.40
Aortic stenosis: mild (n, %) 5 (50%) None -
Peak aortic velocity (cm/sec) 217.5 ± 43.3 174.4 ± 45.8 0.001*
Peak wall shear rate (sec-1) 285.1 ± 18.9 180.1 ± 20.7 0.001*
Aortic insufficiency: 3 (30%) 2 (15%) 0.02*
Trace (n, %) 4 (40%) 1 (7.7%)
Mild (n, %)
Risk factors (n)
Hypertension 5 (50%) 5 (38%) 0.60
Hypercholesterolemia 4 (40%) 6 (46%) 0.85
Coronary artery disease 1 (10%) 2 (15%) 0.20
Tobacco use 1 (10%) 3 (23%) 0.72
Diabetes mellitus 1 (10%) 1 (7.7%) 0.44
Medications (n)
ASA 4 (40%) 2 (15%) 0.72
Anti-coagulants 1 (10%) 2 (15%) 0.20
Beta-blockers 5 (50%) 3 (23%) 0.72
ACE inhibitors/ARB 3 (30%) 3 (23%) 0.42
Statins 3 (30%) 2 (15%) 0.85
Shown are the mean ± standard deviation of the mean.
Warner et al. BMC Cardiovascular Disorders 2013, 13:19 Page 3 of 6
http://www.biomedcentral.com/1471-2261/13/19using analysis of variance for continuous variables. Chi-
square tests were used to compare categorical variables. All
data analysis was carried out using Statistical Package for
the Social Sciences (SPSS, v 16.0, SPSS, Inc., Chicago, IL).
Results
Patient characteristics are listed in Table 1 and show that
the two groups were well-matched. Both ascending aorta
and aortic root size indexed to body size were similar in
both groups. There was a significant difference in aortic
peak velocity and wall shear rate in BAV subjects compared
to TAV controls (Table 1). A total of 10 BAV patients and
13 TAV controls underwent measures of cb-PWV, cr-PWV
and augmentation index. Three patients (1 BAV and 2
TAV) were excluded from the cf-PWV analysis due to poor
femoral arterial waveforms. There was no statistical differ-
ence in Zc, cf-PWV, cb-PWV or cr-PWV between BAV
subjects and TAV controls respectively (Table 2). Similarly,
there were no group differences in effective arterial
elastance (Table 2). By comparison, BAV participants were
found to have significantly larger augmentation indexes
compared to TAV controls (Figure 1). This difference in
AIx persisted after adjusting for sex, height, and heart rate
with analysis of covariance (adjusted means: 14.0%
vs −2.8%, p < 0.05). Moreover, adjusting for ascending aortic
diameter using a separate model also had no effect on
group differences in AIx (adjusted means: 12.5% vs −1.7%,
p < 0.05). AIx was significantly correlated with peak aortic
velocity (r = 0.45, p = 0.02) and peak wall shear rate (r =
0.49, p < 0.05). Adjusting for either peak aortic velocity
(p = 0.11) or peak wall shear rate (p = 0.12) abolished group
differences in AIx.
Discussion
This study demonstrates that in the setting of a normal
ascending aorta size, aortic PWV and arterial elastance
appear similar between subjects with BAV and those
without. By comparison, BAV participants were found to
have a significantly elevated AIx compared to controls.
The increased pressure from wave reflections was inde-
pendent of sex, height and heart rate [18-20]. This find-
ing is clinically significant as increased AIx is associated
with increased risk of future CV events [21].
We noted elevated AIx in BAV in the absence of ele-
vated aortic PWV and this is novel. Previous studies not-
ing increased AIx in BAV were carried out in patients
with aortic dilation [22,23]. This is important as patients
with BAV and dilated aortas have increased aortic PWV
compared to BAV patients with preserved aortic size
[24]. Dilation of the vessel transposes load bearing from
elastin fibers to stiffer collagen fibers, increasing the
incremental elastic modulus of the vessel [25,26].
According to the Moens-Korteweg equation, this in-
crease in elastic modulus will increase PWV. Whetherincreased AIx was secondary to increased aortic stiffness
(from altered wave speed) or an independent phenotypic
expression of this unique pathology could not be
disentangled. Our findings offer important insight into
the arteriopathy associated with BAV and suggest in-
creased pressure from wave reflections as a primary sys-
temic vascular aberration in BAV in the absence of
aortic dilation, subsequent stiffening and altered reflec-
tion timing. These findings suggest a role for down-
stream microvascular dysfunction distal to the aorta as a
Table 2 Study results
Arterial Stiffness Parameter BAV TAV p-value
Characteristic Impedance (Zc) 146.50 ± 14.69 177.54 ± 20.12 0.25
Carotid-Femoral PWV (cm/sec) 781.43 ± 92.51 782.26 ± 67.02 0.99
Carotid-Brachial PWV (cm/sec) 796.14 ± 55.67 789.22 ± 50.44 0.93
Carotid-Radial PWV (cm/sec) 952.65 ± 49.59 940.11 ± 42.64 0.85
Arterial elastance (mmHg/ml) 1.63 ± 0.59 1.94 ± 0.57 0.26
Time to inflection, ms 129 ± 12 141 ± 9 0.39
Augmentation Index (%) 14.27 ± 4.18 -3.02 ± 3.96 0.007*
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from wave reflections in BAV.
A novel observation in the present study was the asso-
ciation between AIx and peak wall shear offering insight
into observations of higher AIx in the setting of BAV.
BAV patients with normal aortic geometry had higher
wall shear than TAV due to higher aortic flow velocity
and this is consistent with previous reports noted in
BAV patients with dilated aortas and/or aneurysms
[27,28]. Altered valve hemodynamics have been impli-
cated in the cause of aortic root dilation [29,30],
aneurysm [31] and valve calcification [32,33] in BAV.
Such altered central hemodynamics [34] may also dam-
age the peripheral microvasculature [35], altering reflec-
tion sites and contributing to increased reflected
pressure wave magnitude. It is interesting to note that
valve replacement and normalization of aberrant central
flow profiles in BAV does not mitigate aortic dilation
progression [11]. Abnormalities in AIx reported herein,
and elsewhere [22,23], may reflect a previously unsus-
pected role for increased pressure from wave reflections
in the development of large vessel arteriopathy in pa-











Figure 1 Subjects with BAV have significantly greater AIx
compared with subjects with a TAV. Carotid AIx was measured by
applantation tonometry; AIx was significantly (asterisk, p = 0.007)
greater in BAV subjects compared with TAV subjects.Marfan syndrome, increased AIx has been shown to pre-
dict progression of aortic disease [36,37]. It has been
suggested that pressure pulsatility and cyclic stress from
wave reflections alter load-bearing capacity of the aortic
wall and contribute to fatigue-fracture (i.e. mechanical
failure of biomaterials), increasing risk for aortic dilation
and aneurysm [38]. The etiology of AIx as it relates to
aortopathy in BAV requires further investigation.
The results of our prospective analysis finding no dif-
ferences in PWV and arterial elastance between BAV
and TAV patients is supported by studies showing no
difference in serum matrix metalloprotein-2 levels in
BAV without aneurysms compared to normal controls
[24]. In addition, gene expression profiles of aorta tissue
taken from BAV and TAV patients without aneurysm are
very similar [39]. Our results differ from studies that
demonstrated abnormal aortic root distensibility and
stiffness index in BAV patients without aneurysms
[40-42]. Discrepancy is likely related to method of meas-
urement as these previous studies relied on imaging mo-
dalities such as echocardiography. Our findings are in
agreement with others [22,24] demonstrating normal
aortic stiffness as measured using PWV in BAV patients
without aneurysms. PWV is considered to be a robust
measure of aortic stiffness and is currently viewed as the
“gold standard” for measuring aortic stiffness [18-20].
We acknowledge several limitations in our study. First,
since our primary hypothesis was that abnormal aortic
stiffness would be found in the setting of BAV we con-
sider our observation of increased AIx to be hypothesis
generating. Second, the small size of our study may limit
the generalizability of our results to the broader popula-
tion of patients with BAV. We noted a partial η2 of 0.47
with an observed power of 0.79 signifying moderate ef-
fect size with adequate power for detecting group differ-
ences in AIx. Thus although possibility of a type II error
exists, we believe it to be low.
Conclusions
Normal aortic stiffness with normal aortic dimension
suggests that the ascending aorta is not invariably abnor-
mal in the setting of BAV, despite the predisposition for
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motivate further investigation into the impact of the per-
ipheral vasculature on the central vascular phenotype in
BAV patients as long term abnormalities may contribute
to subsequent ascending aortic dilation and aneurysm
formation in patients with BAV.
Our study demonstrates that arterial stiffness and
elastance are similar between subjects with BAV and TAV
with normal aortic dimensions. At the same time we dem-
onstrate a higher carotid AIx in BAV patients consistent
with abnormal vascular properties distal to the aorta. Fu-
ture studies are required to determine whether abnormal
distal arterial properties in BAV subjects contribute to prox-
imal aortic dilation and aneurysm formation.
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